NCT02775799

Brief Summary

Registration of all sarcoma patients treated at a specialized sarcoma center in Switzerland.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2015

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

May 16, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 18, 2016

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

October 2, 2018

Status Verified

September 1, 2018

Enrollment Period

3.3 years

First QC Date

May 16, 2016

Last Update Submit

September 30, 2018

Conditions

SarcomaNeoplasm of BoneNeoplasmsSoft Tissue SarcomaSoft Tissue NeoplasmSarcoma of Bone

Outcome Measures

Primary Outcomes (1)

  • Overall survival rate

    up to 20 years after first line treatment

Interventions

RegistrationOTHER

Registration according to approved data sets

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients diagnosed with histo- pathological proven sarcoma

You may qualify if:

  • all primary bone and soft tissue sarcoma defined by th WHO classification 2013

You may not qualify if:

  • all non- primary sarcomas
  • patient's wish

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Balgrist University Hospital

Zurich, 8008, Switzerland

Location

MeSH Terms

Conditions

SarcomaBone NeoplasmsNeoplasmsSoft Tissue NeoplasmsOsteosarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms by SiteBone DiseasesMusculoskeletal DiseasesNeoplasms, Bone TissueNeoplasms, Connective Tissue

Study Officials

  • Bruno Fuchs, MD PhD

    Balgrist UH

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
20 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 16, 2016

First Posted

May 18, 2016

Study Start

April 1, 2015

Primary Completion

July 1, 2018

Study Completion

July 1, 2018

Last Updated

October 2, 2018

Record last verified: 2018-09

Data Sharing

IPD Sharing
Will share

Assessed data shall be shared with the National Institute for Cancer Epidemiology an Registration and the cantonal cancer registers

Locations

CH(1)